UBS analyst Cody Ross maintains Beyond Meat (NASDAQ:BYND) with a Neutral and raises the price target from $20 to $30.
Coeptis Therapeutics Secures Exclusive Rights To Negotiate To Acquire Transformational Cell Therapy Platform To Enable Potent Combinatorial Immuno-Oncology Treatment Strategies
Potential acquisition of VyGen-Bio would strengthen Coeptis' oncology pipeline by obtaining exclusive, worldwide ownership rights to GEAR™ Platform and companion diagnostic technologies
WEXFORD,